Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 12, 2024Canadian Journal of Health Technologies

Thrombopoietin Receptor Agonists as Second-Line Treatment in Children With Ongoing Immune Thrombocytopenia

View Full Paper
Ask AI
Bookmark
Share

Authors

CCADTH

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

CADTH (2024) studied this question.

synapsesocial.com/papers/68e58bb0b6db643587527dfdhttps://doi.org/10.51731/cjht.2024.974
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world experience of thrombopoietin receptor agonists in pediatric immune thrombocytopenia: a report from a Chinese tertiary children’s hospital2024 · 1 citations
  2. 2Is switching to romiplostim still worthwhile after failure of multiple oral TPO-RAs in pediatric refractory ITP?2026
  3. 3When Platelet Stimulation Becomes Marrow Stress: Rethinking Thrombopoietin Receptor Agonist Intensification in Pediatric Immune Thrombocytopenia2026
  4. 4Efficacy and safety of romiplostim N01 for second-line treatment of pediatric immune thrombocytopenia: A multicenter prospective observational study2025
  5. 5Treatment opportunities for refractory immune thrombocytopenia2024 · 1 citations